<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title>Title</title></head><body><div><p style="margin:0pt; text-align:center"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:bold">Written evidence from Gilead Sciences (LTC 87)</span></p><p style="margin:0pt; text-align:center"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:bold">Executive summary</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:4.14pt; text-align:justify; text-indent:0pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">Treatment i</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">nnovation has transformed HIV into a long term condition. </span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:4.14pt; text-align:justify; text-indent:0pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">The management of HIV requires special consideration due to its infectious nature.</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:4.14pt; text-align:justify; text-indent:0pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">Ageing in HIV presents significant challenges for the NHS in terms of managing care, complex treatment plans and co-morbidities.</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:4.14pt; text-align:justify; text-indent:0pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">HIV treatments are cost effective because they </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">significantly </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">reduce the risk of onward transmission and HIV related illnesses</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">.</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> However </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">a major threat to the effectiveness of HIV treatment is non-adherence.</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:4.14pt; text-align:justify; text-indent:0pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">New treatments </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">may</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> improve adherence </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">which in turn may</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> ensure patients are healthier, require fewer hospital admissions, and reduce the risk of transmission. All of these outcomes improve value for money for the NHS.</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 10.06pt; padding-left:4.14pt; text-align:justify; text-indent:0pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">If we do not continue to innovate and invest in HIV, there may be a reversal of the progress we have made so far and an escalation of HIV over time. </span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:bold">Introduction</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">&#xa0;</span></p><ol type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; list-style-position:inside; margin:0pt; text-align:justify; text-indent:0pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">Gilead is </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">a</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> leading provider of HIV medicines to NHS patients. We welcome the opportunity to respond to the Health Select Committee’s inquiry into the management of long term conditions. Our response focuses on the effectiveness of service provision and treatment for people with HIV.</span></li></ol><p style="margin:0pt 0pt 0pt 21.3pt; text-align:justify; text-indent:-21.3pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">&#xa0;</span></p><ol start="2" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; list-style-position:inside; margin:0pt; text-align:justify; text-indent:0pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">HIV treatment has advanced dramatically in the decades since the discovery of the virus. Patient prospects have improved </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">considerably</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> and patients can now expect to have a near normal life expectancy. As patients are living longer with HIV their needs are changing. This means the number of patients and overall costs are rising rapidly.</span></li></ol><p style="margin:0pt 0pt 0pt 21.3pt; text-align:justify; text-indent:-21.3pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">&#xa0;</span></p><ol start="3" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; list-style-position:inside; margin:0pt; text-align:justify; text-indent:0pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">Unlike many other long term conditions, HIV is also infectious. </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">To </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">slow the increase in</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> the number of patients and costs,</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> a two-pronged strategy of early diagnosis and access to treatment</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> is required</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">. Late diagnosis, by contrast, is associated with a greater risk of hospitalisation and AIDS-related illness, reduced life expectancy and increased cost to the NHS. It is also associated with increased onward transmission, and continued sexual risk-taking while people are unaware of their HIV-positive status.</span></li></ol><p style="margin:0pt 0pt 0pt 21.3pt; text-align:justify; text-indent:-21.3pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">&#xa0;</span></p><ol start="4" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; list-style-position:inside; margin:0pt; text-align:justify; text-indent:0pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">Gilead</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> recommend</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">s</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> the development of a comprehensive strategy for HIV, that will update current NHS practice in line with the treatments and services patients require today.</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> Further innovation will enable patients to better manage their condition, prolong life expectancy</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> and</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> reduce the risk of transmitting the virus to others.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:bold">Ageing and HIV</span></p><p style="margin:0pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">&#xa0;</span></p><ol start="5" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; list-style-position:inside; margin:0pt; text-align:justify; text-indent:0pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">Since 2000 there has been a three-fold increase in the number of individuals accessing HIV care and a fourfold increase among people over the age of 50.</span><a name="_ftnref1"></a><a href="#_ftn1">[1]</a><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">This presents significant challenges for the NHS in terms of managing care, complex treatment plans and co-morbidities.</span></li></ol><p style="margin:0pt 0pt 0pt 21.3pt; text-align:justify; text-indent:-21.3pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">&#xa0;</span></p><ol start="6" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; list-style-position:inside; margin:0pt; text-align:justify; text-indent:0pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">C</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">urrent scientific debate on the impact of HIV related premature ageing</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">suggest</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> that</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">we will </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">see an increasing incidence and prevalence of common age related co-morbidities (such as cardiovascular disease, coronary heart disease, chronic kidney disease and cancers)</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">.</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">This will </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">requir</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">e</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> the need for less toxic HIV treatments with fewer drug-drug interactions. </span></li></ol><p style="margin:0pt 0pt 0pt 21.3pt; text-align:justify; text-indent:-21.3pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">&#xa0;</span></p><ol start="7" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; list-style-position:inside; margin:0pt; text-align:justify; text-indent:0pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">The issue of changing patient needs are particularly relevant given the reality of the ageing HIV patient population in the UK over the next five years. Currently many existing medications for common medical conditions have drug interactions, are contraindicated for certain HIV treatments and/or require enhanced diagnostic monitoring. </span></li><li style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; list-style-position:inside; margin:0pt; text-align:justify; text-indent:0pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">It is important that we develop new HIV treatments that can be safely used alongside medicines for other common medical conditions to protect patients and reduce the strain on the healthcare system.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:bold">Adherence to treatment</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">&#xa0;</span></p><ol start="9" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; list-style-position:inside; margin:0pt; text-align:justify; text-indent:0pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">HIV treatment </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">is highly </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">cost effective</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">, </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">reduc</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">ing</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> the risk of onward transmission by 96%</span><a name="_ftnref2"></a><a href="#_ftn2">[2]</a><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> and HIV related illnesses by 41%. However </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">a major threat to the effectiveness of HIV treatment is non-adherence. </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">Adherence to treatment is </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">very important in helping to ensure a positive outcome</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> for patients</span><a name="_ftnref3"></a><a href="#_ftn3">[3]</a><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">. </span></li></ol><p style="margin:0pt 0pt 0pt 21.3pt; text-align:justify; text-indent:-21.3pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">&#xa0;</span></p><ol start="10" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; list-style-position:inside; margin:0pt; text-align:justify; text-indent:0pt"><span style="font:7.0pt 'Times New Roman'">&#xa0; </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">There are a number of factors that inhibit patient adherence to treatment, among them: impact of side effects, fear of disclosure of their HIV status, substance abuse and difficulty in managing multiple tablets</span><a name="_ftnref4"></a><a href="#_ftn4">[4]</a><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">.</span></li></ol><p style="margin:0pt 0pt 0pt 21.3pt; text-align:justify; text-indent:-21.3pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">&#xa0;</span></p><ol start="11" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; list-style-position:inside; margin:0pt; text-align:justify; text-indent:0pt"><span style="font:7.0pt 'Times New Roman'">&#xa0; </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">Missed doses of treatment have been shown to lead to treatment failure,</span><a name="_ftnref5"></a><a href="#_ftn5">[5]</a><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> increasing both the rate of progression to AIDS</span><a name="_ftnref6"></a><a href="#_ftn6">[6]</a><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> and the risk of resistance to treatment.</span><a name="_ftnref7"></a><a href="#_ftn7">[7]</a><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> Non-adherence has been shown to make patients almost twice as likely to require hospital admission.</span><a name="_ftnref8"></a><a href="#_ftn8">[8]</a><span style="font-family:'Frutiger LT Std 45 Light'; font-size:7.33pt; vertical-align:super">.</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">An increase in adherence by just 10% has been shown to reduce the risk of progression to AIDS by 28%.</span><a name="_ftnref9"></a><a href="#_ftn9">[9]</a><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> </span></li></ol><p style="margin:0pt 0pt 0pt 21.3pt; text-align:justify; text-indent:-21.3pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">&#xa0;</span></p><ol start="12" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; list-style-position:inside; margin:0pt; text-align:justify; text-indent:0pt"><span style="font:7.0pt 'Times New Roman'">&#xa0; </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">Given all these factors, supporting full adherence to treatment is </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">a key factor in</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> the long-term affordability of high quality care. </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">New treatments that are easier to manage and have reduced side effects will be </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">important in helping to achieve</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> consistent adherence to maximise </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">virological</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> suppression, improve patients’ quality of life and </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">helping to </span><a name="_GoBack"></a><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">minimise healthcare resource use.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:bold">Conclusion</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">&#xa0;</span></p><ol start="13" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; list-style-position:inside; margin:0pt; text-align:justify; text-indent:0pt"><span style="font:7.0pt 'Times New Roman'">&#xa0; </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">Gilead</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> recommend</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">s</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> the development of a comprehensive strategy for HIV, that will update current NHS practice in line with the treatment and services patients require today.</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">The strategy should include the development of appropriate quality measures focused on quality of care and patient experience and choice.</span></li></ol><p style="margin:0pt 0pt 0pt 21.3pt; text-align:justify"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">&#xa0;</span></p><ol start="14" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; list-style-position:inside; margin:0pt; text-align:justify; text-indent:0pt"><span style="font:7.0pt 'Times New Roman'">&#xa0; </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">In particular, the increasing </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">and </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">ageing population with HIV presents an urgent need for services to be adapted to meet future demand.</span></li></ol><p style="margin:0pt 0pt 0pt 21.3pt; text-align:justify; text-indent:-21.3pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">&#xa0;</span></p><ol start="15" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; list-style-position:inside; margin:0pt; text-align:justify; text-indent:0pt"><span style="font:7.0pt 'Times New Roman'">&#xa0; </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">P</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">atients </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">must continue to </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">have early access to the treatment</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> regimens of their choice</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> and support to remain adherent to treatment plans</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> in order to</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> improve the quality of long-term outcomes, reduce avoidable poor health</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">,</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> minimise the risk of onward transmission</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> and manage costs to the NHS.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-style:italic">May 2013</span></p><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:10pt; font-style:italic">&#xa0;</span></p></div><hr style="width:33%; height:1px; text-align:left" /><p style="margin:0pt"><a name="_ftn1"></a><a href="#_ftnref1">[1]</a><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt"> HIV in the United Kingdom: 2010 Report, Health Protection Agency, November 2010</span></p><p style="margin:0pt"><a name="_ftn2"></a><a href="#_ftnref2">[2]</a><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">Cohen, M., Chen, Y., &amp; McCauley, M. (2011). </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt; font-style:italic">Prevention of HIV-1 infection with early antiretroviral therapy</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">. New England Journal of Medicine, 365(6), 493-505.</span></p><p style="margin:0pt"><a name="_ftn3"></a><a href="#_ftnref3">[3]</a><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt"> Glass, T., </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">Geest</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">, S. D., &amp; </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">Hirschel</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">, B; </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">Battegay</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">, M; </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">Furrer</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">, H, </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">Cavassini</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">, M; </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">Vernazza</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">, P; </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">Bernasconi</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">, E; </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">Rickenbach</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">, M; Weber, R; Bucher, H. S. H. C. S. (2008). </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt; font-style:italic">Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt; font-style:italic">virologically</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt; font-style:italic"> suppressed patients</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">. Antiviral Therapy, 13, 77-85.</span></p><p style="margin:0pt"><a name="_ftn4"></a><a href="#_ftnref4">[4]</a><span style="font-family:'Frutiger LT Std 45 Light'; font-size:6pt; vertical-align:super"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">Gazzard, B. G., Anderson, J., Babiker, A., Boffito, M., Brook, G., Brough, G., Churchill, D., et al. (2008). British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV medicine, 9(8), 563-608</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:6pt; vertical-align:super">.</span></p><p style="margin:0pt"><a name="_ftn5"></a><a href="#_ftnref5">[5]</a><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt"> Glass, T., Geest, S.D., &amp;</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">&#xa0;</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">Hirschel,</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">&#xa0;</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">B; Battegay,</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">&#xa0;</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">M; Furrer, H,</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">&#xa0;</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">Cavassini, M; Vernazza, P;</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">&#xa0;</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">Bernasconi, E;</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">&#xa0;</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">Rickenbach, M; Weber, R; Bucher,</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">&#xa0;</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">H.S.H.C.S.(2008). </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt; font-style:italic">Self-­</span><span style="font-family:Calibri; font-size:9pt; font-style:italic">‐</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt; font-style:italic">reported non-­</span><span style="font-family:Calibri; font-size:9pt; font-style:italic">‐</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt; font-style:italic">adherence</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt; font-style:italic">&#xa0;</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt; font-style:italic">to antiretroviral</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt; font-style:italic">&#xa0;</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt; font-style:italic">therapy repeatedly</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt; font-style:italic">&#xa0;</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt; font-style:italic">assessed</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt; font-style:italic">&#xa0;</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt; font-style:italic">by</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt; font-style:italic">&#xa0;</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt; font-style:italic">two</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt; font-style:italic">&#xa0;</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt; font-style:italic">questions</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt; font-style:italic">&#xa0;</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt; font-style:italic">predicts treatment</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt; font-style:italic">&#xa0;</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt; font-style:italic">failure</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt; font-style:italic">&#xa0;</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt; font-style:italic">in</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt; font-style:italic">&#xa0;</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt; font-style:italic">virologically</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt; font-style:italic">&#xa0;</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt; font-style:italic">suppressed patients</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">. Antiviral</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">&#xa0;</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">Therapy,</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">&#xa0;</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">13,77-­</span><span style="font-family:Calibri; font-size:9pt">‐</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">85.</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">              </span></p><p style="margin:0pt"><a name="_ftn6"></a><a href="#_ftnref6">[6]</a><span style="font-family:'Frutiger LT Std 45 Light'; font-size:6pt; vertical-align:super"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">Bangsberg</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">, D. R., Perry, S., </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">Charlebois</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">, E. D., Clark, R. a, </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">Roberston</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">, M., </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">Zolopa</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">, a R., &amp; Moss, a. (2001). Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS (London, England), 15(9), 1181-3.</span></p><p style="margin:0pt"><a name="_ftn7"></a><a href="#_ftnref7">[7]</a><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">Bangsberg</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">, D. R. (2008). </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt; font-style:italic">Preventing HIV antiretroviral resistance through better monitoring of treatment adherence</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">. Journal of Infectious Diseases, 197 </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">Suppl</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">(</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">Suppl</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt"> 3), S272-8.</span></p><p style="margin:0pt"><a name="_ftn8"></a><a href="#_ftnref8">[8]</a><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">Fielden</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">, S.J., et al., </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt; font-style:italic">Nonadherence</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt; font-style:italic"> increases the risk of hospitalisation among HIV-infected antiretroviral naïve patients started on HAART</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">, 2008</span></p><p style="margin:0pt"><a name="_ftn9"></a><a href="#_ftnref9">[9]</a><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">Bangsberg</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">, D. R., Perry, S., </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">Charlebois</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">, E. D., Clark, R. a, </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">Roberston</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">, M., </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">Zolopa</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">, a R., &amp; Moss, a. (2001). Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS (London, England), 15(9), 1181-3.</span></p></body></html>